Roivant Sciences Ltd. has grown revenue −36% a year over three years and −24% a year over five. Revenue growth, 3-year annual rate: −36% (Biotechnology median +17%). Revenue growth, 5-year rate: −24%, growth has slowed since the five-year average. Years of annual history on file: 6, FY2020 to FY2025, as filed.

ROIVRoivant Sciences Ltd.

Healthcare

$35.42+136% 1Y

$35.42

$14.7052 weeks$41.81

Is it growing?

Watch

Growth is fading: revenue shrinking (−68% year on year) and operating margin narrowing (−4447.3 points).

2 to watch, 1 without data

Revenue trend−68% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: −24% a year.

Margin direction−4447.3 points operating

Trailing-twelve-month operating margin, -11340.5% now against -6893.3% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is ROIV growing?

Roivant Sciences Ltd. has grown revenue −36% a year over three years and −24% a year over five.

−36%

Revenue growth, 3-year annual rate · Biotechnology median +17% · shrinking · compounded from fiscal-year columns as filed

Revenue growth, 5-year rate: −24%
Revenue growth, 5-year rate · −36% over three · growth has slowed since the five-year average
Years of annual history on file: 6
Years of annual history on file · FY2020 to FY2025, as filed

Details›